CD274 and non-small cell lung carcinoma: Today, the advent of immunotherapy with immune checkpoint inhibitors targeting the PD-1 receptor and its PD-L1 ligand has become a great help for NSCLC patients, particularly in the absence of associated driver mutations [14,15].